scholarly journals Comparison of [18F]FDG PET/CT and MRI for Treatment Response Assessment in Multiple Myeloma: A Meta-Analysis

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 706
Author(s):  
Kota Yokoyama ◽  
Junichi Tsuchiya ◽  
Ukihide Tateishi

The present study was designed to assess the additional value of 2-deoxy-2[18F]fluoro-D-glucose ([18F]FDG) positron emission tomography/computed tomography (PET/CT) to magnetic resonance imaging (MRI) in the treatment response assessment of multiple myeloma (MM). We performed a meta-analysis of all available studies to compare the detectability of treatment response of [18F]FDG PET/CT and MRI in treated MM. We defined detecting a good therapeutic effect as positive, and residual disease as negative. We determined the sensitivities and specificities across studies, calculated the positive and negative likelihood ratios (LR), and made summary receiver operating characteristic curves (SROC) using hierarchical regression models. The pooled analysis included six studies that comprised 278 patients. The respective performance characteristics (95% confidence interval (CI)) of [18F]FDG PET/CT and MRI were as follows: sensitivity of 80% (56% to 94%) and 25% (19% to 31%); specificity of 58% (44% to 71%) and 83% (71% to 91%); diagnostic odds ratio (DOR) of 6.0 (3.0–12.0) and 1.7 (0.7–2.7); positive LR of 1.8 (1.3–2.4) and 1.4 (0.7–2.7); and negative LR of 0.33 (0.21–0.53) and 0.81 (0.62–1.1). In the respective SROC curves, the area under the curve was 0.77 (SE, 0.038) and 0.59 (SE, 0.079) and the Q* index was 0.71 and 0.57. Compared with MRI, [18F]FDG PET/CT had higher sensitivity and better DOR and SROC curves. Compared with MRI, [18F]FDG PET/CT had greater ability to detect the treatment assessment of MM.

2013 ◽  
Vol 38 (4) ◽  
pp. e185-e187 ◽  
Author(s):  
Giorgio Treglia ◽  
Silvia Taralli ◽  
Fabio Maggi ◽  
Antonella Coli ◽  
Libero Lauriola ◽  
...  

2019 ◽  
Vol 57 ◽  
pp. 177-182 ◽  
Author(s):  
Carlotta Dolci ◽  
Chiara Spadavecchia ◽  
Cinzia Crivellaro ◽  
Elena De Ponti ◽  
Sergio Todde ◽  
...  

2014 ◽  
Vol 83 (10) ◽  
pp. 1925-1933 ◽  
Author(s):  
David Groheux ◽  
Elif Hindié ◽  
Michel Marty ◽  
Marc Espié ◽  
Domenico Rubello ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Xianwen Hu ◽  
Dandan Li ◽  
Zhigang Liang ◽  
Yan Liao ◽  
Ling Yang ◽  
...  

Abstract Objective To compare the value of fluorodeoxyglucose positron emission tomography (FDG-PET)/computed tomography (CT) and magnetic resonance imaging (MRI) in differentiating benign and malignant ovarian or adnexal tumors. Materials and methods English articles reporting on the diagnostic performance of MRI or 18F-FDG PET/CT in identifying benign and malignant ovarian or adnexal tumors published in PubMed and Embase between January 2000 and January 2021 were included in the meta-analysis. Two authors independently extracted the data. If the data presented in the study report could be used to construct a 2 × 2 contingency table comparing 18F-FDG PET/CT and MRI, the studies were selected for the analysis. The Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) was used to evaluate the quality of the included studies. Forest plots were generated according to the sensitivity and specificity of 18F-FDG PET/CT and MRI. Results A total of 27 articles, including 1118F-FDG PET/CT studies and 17 MRI studies on the differentiation of benign and malignant ovarian or adnexal tumors, were included in this meta-analysis. The pooled sensitivity and specificity for 18F-FDG PET/CT in differentiating benign and malignant ovarian or adnexal tumors were 0.94 (95% CI, 0.87–0.97) and 0.86 (95% CI, 0.79–0.91), respectively, and the pooled sensitivity and specificity for MRI were 0.92 (95% CI: 0.89–0.95) and 0.85 (95% CI: 0.79–0.89), respectively. Conclusion While MRI and 18F-FDG PET/CT both showed to have high and similar diagnostic performance in the differential diagnosis of benign and malignant ovarian or adnexal tumors, MRI, a promising non-radiation imaging technology, may be a more suitable choice for patients with ovarian or accessory tumors. Nonetheless, prospective studies directly comparing MRI and 18F-FDG PET/CT diagnostic performance in the differentiation of benign and malignant ovarian or adnexal tumors are needed.


2012 ◽  
Vol 81 (2) ◽  
pp. 303-311 ◽  
Author(s):  
Lian-Ming Wu ◽  
Fang-Yuan Chen ◽  
Xiao-Xing Jiang ◽  
Hai-Yan Gu ◽  
Yan Yin ◽  
...  

2013 ◽  
Vol 40 (6Part9) ◽  
pp. 197-197
Author(s):  
L Rankine ◽  
J Bowsher ◽  
D Brizel ◽  
F Yin ◽  
S Das

Sign in / Sign up

Export Citation Format

Share Document